Published in Med Oncol on January 16, 2009
CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res (2012) 4.56
Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Res (2012) 1.17
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther (2010) 1.10
IRX-2, a novel biologic, favors the expansion of T effector over T regulatory cells in a human tumor microenvironment model. J Mol Med (Berl) (2011) 0.81
Comparison of vascular leak syndrome in mice treated with IL21 or IL2. Comp Med (2013) 0.80
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med (2005) 6.86
Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res (2011) 5.40
Interleukin-17 promotes angiogenesis and tumor growth. Blood (2002) 4.90
Endogenous HMGB1 regulates autophagy. J Cell Biol (2010) 4.71
Inflammation and necrosis promote tumour growth. Nat Rev Immunol (2004) 3.68
The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev (2007) 3.33
High-mobility group box 1 and cancer. Biochim Biophys Acta (2010) 3.11
Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet (2010) 3.02
IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol (2005) 3.02
Interleukin-12: biological properties and clinical application. Clin Cancer Res (2007) 3.00
Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol (2007) 2.81
Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. J Immunol (2005) 2.78
RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med (2009) 2.56
Masquerader: high mobility group box-1 and cancer. Clin Cancer Res (2007) 2.40
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev (2012) 2.24
High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal (2011) 2.19
Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol (2007) 2.12
Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat Genet (2012) 2.02
Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proc Natl Acad Sci U S A (2009) 1.94
Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine (2002) 1.92
Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice. Hepatology (2004) 1.92
High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab (2011) 1.89
Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother (2004) 1.88
Treatment of hepatic epithelioid hemangioendothelioma: a single-institution experience with 25 cases. Arch Surg (2009) 1.82
Second-generation tetracycline-regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness. J Gene Med (2004) 1.80
Autophagy inhibition in combination cancer treatment. Curr Opin Investig Drugs (2009) 1.79
HMGB1 in cancer: good, bad, or both? Clin Cancer Res (2013) 1.79
Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A (2010) 1.72
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Divergent roles of Smad3 and PI3-kinase in murine adriamycin nephropathy indicate distinct mechanisms of proteinuria and fibrogenesis. Kidney Int (2012) 1.66
Posttransplant biliary complications in the pre- and post-model for end-stage liver disease era. Liver Transpl (2011) 1.63
Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma. Clin Gastroenterol Hepatol (2009) 1.60
Feature Selection for Classification of SELDI-TOF-MS Proteomic Profiles. Appl Bioinformatics (2005) 1.56
Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol Lett (2004) 1.46
High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother (2007) 1.45
Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol (2009) 1.45
High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology (2012) 1.42
Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. J Immunol (2006) 1.42
Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses. J Exp Med (2002) 1.41
Subclinical impairment of ovarian reserve in systemic lupus erythematosus patients with normal menstruation not using alkylating therapy. J Womens Health (Larchmt) (2013) 1.41
p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res (2012) 1.41
Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. J Immunother (2007) 1.39
Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1. Mol Immunol (2005) 1.39
The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res (2005) 1.34
Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function. Am J Respir Cell Mol Biol (2009) 1.32
Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-kappa B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig. J Immunol (2002) 1.32
Receptor-mediated signalling in plants: molecular patterns and programmes. J Exp Bot (2009) 1.31
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett (2004) 1.30
The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proc Natl Acad Sci U S A (2012) 1.30
Increasing numbers of hepatic dendritic cells promote HMGB1-mediated ischemia-reperfusion injury. J Leukoc Biol (2006) 1.27
High mobility group box 1 (HMGB1) activates an autophagic response to oxidative stress. Antioxid Redox Signal (2011) 1.27
Dealing with death: HMGB1 as a novel target for cancer therapy. Curr Opin Investig Drugs (2003) 1.24
Bacteremias in liver transplant recipients: shift toward gram-negative bacteria as predominant pathogens. Liver Transpl (2004) 1.22
A Janus tale of two active high mobility group box 1 (HMGB1) redox states. Mol Med (2012) 1.21
Cell-mediated autophagy promotes cancer cell survival. Cancer Res (2012) 1.21
Damage associated molecular pattern molecules. Clin Immunol (2007) 1.19
Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. Transplantation (2003) 1.18
HMGB1: The Central Cytokine for All Lymphoid Cells. Front Immunol (2013) 1.18
Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Res (2012) 1.17
Prevention of diabetes in NOD mice by administration of dendritic cells deficient in nuclear transcription factor-kappaB activity. Diabetes (2003) 1.15
Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol (2006) 1.14
Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther (2005) 1.11
Tumor-cell death, autophagy, and immunity. N Engl J Med (2012) 1.10
Liver biopsy findings from healthy potential living liver donors: reasons for disqualification, silent diseases and correlation with liver injury tests. J Hepatol (2008) 1.08
HMGB1 as an autophagy sensor in oxidative stress. Autophagy (2011) 1.08
Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation. J Clin Invest (2015) 1.08
miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy. J Transl Med (2010) 1.07
High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists. J Immunol (2006) 1.07
MicroRNAs in immune regulation--opportunities for cancer immunotherapy. Int J Biochem Cell Biol (2010) 1.06
The Receptor for Advanced Glycation End-products (RAGE) protects pancreatic tumor cells against oxidative injury. Antioxid Redox Signal (2011) 1.05
Tumor immunity times out: TIM-3 and HMGB1. Nat Immunol (2012) 1.04
Ethyl pyruvate administration inhibits hepatic tumor growth. J Leukoc Biol (2009) 1.04
The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells. J Immunol (2012) 1.03
DAMPs and autophagy: cellular adaptation to injury and unscheduled cell death. Autophagy (2013) 1.02
Oxaliplatin retains HMGB1 intranuclearly and ameliorates collagen type II-induced arthritis. Arthritis Res Ther (2008) 1.02
Premature progesterone rise negatively correlated with live birth rate in IVF cycles with GnRH agonist: an analysis of 2,566 cycles. Fertil Steril (2012) 1.01
Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-κB pathways. Oncol Rep (2012) 1.01
Life after death: targeting high mobility group box 1 in emergent cancer therapies. Am J Cancer Res (2013) 1.01
Genotype-phenotype correlations of PCOS susceptibility SNPs identified by GWAS in a large cohort of Han Chinese women. Hum Reprod (2012) 1.00
Individual and environmental correlates and predictors of early adherence and outcomes after liver transplantation. Prog Transplant (2010) 0.99
Pivotal advance: inhibition of HMGB1 nuclear translocation as a mechanism for the anti-rheumatic effects of gold sodium thiomalate. J Leukoc Biol (2007) 0.98
AGER/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway. Autophagy (2012) 0.98
Innate immunity mediated by the cytokine IL-1 homologue 4 (IL-1H4/IL-1F7) induces IL-12-dependent adaptive and profound antitumor immunity. J Immunol (2003) 0.98
Low-dose cisplatin administration in murine cecal ligation and puncture prevents the systemic release of HMGB1 and attenuates lethality. J Leukoc Biol (2009) 0.97
Zinc in innate and adaptive tumor immunity. J Transl Med (2010) 0.95
Pediatric cancers are infiltrated predominantly by macrophages and contain a paucity of dendritic cells: a major nosologic difference with adult tumors. Clin Cancer Res (2006) 0.95
Exposure to lipid-rich follicular fluid is associated with endoplasmic reticulum stress and impaired oocyte maturation in cumulus-oocyte complexes. Fertil Steril (2012) 0.94
C16 ceramide accumulates following androgen ablation in LNCaP prostate cancer cells. Prostate (2003) 0.93
Paucity of dendritic cells in pancreatic cancer. Surgery (2002) 0.93
Hypoxia-inducible factor-2α and TGF-β signaling interact to promote normoxic glomerular fibrogenesis. Am J Physiol Renal Physiol (2013) 0.93
RAGE regulates autophagy and apoptosis following oxidative injury. Autophagy (2011) 0.93
Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells. J Immunother (2011) 0.92
Metabolic regulation by HMGB1-mediated autophagy and mitophagy. Autophagy (2011) 0.92
A life in passing: Jonathan Gray. J Transl Med (2007) 0.91